Shire’s Sales, R&D Heads Shed Light On The Post-Baxalta Road Ahead

Shire’s Perry Sternberg and Phil Vickers are optimistic about recent launches and products in late stages of development in key rare disease and specialty therapeutic areas, many of which come from Baxalta and other high-profile acquisitions.

2017

There probably are few things that pharmaceutical sales representatives like more than new products to pitch to doctors and Shire PLC’s Baxalta Inc. buyout last year gave the company’s reps plenty to be happy about.

The excitement is palpable when talking to US Head of Commercial Perry Sternberg about the eight products that Shire recently has launched or expects to launch in 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business